Literature DB >> 2886241

Improving the response to gold or D-penicillamine by addition of sulphasalazine. A pilot study in 25 patients with rheumatoid arthritis.

P T Dawes, T P Sheeran, P D Fowler, M F Shadforth.   

Abstract

In a 6-month open pilot study 25 patients with Rheumatoid Arthritis (RA) whose disease was refractory to Gold or D-Penicillamine (DPA) were given Sulphasalazine (SAS) in addition. Three patients withdrew because of nausea. Twenty-two patients who completed therapy showed significant improvement in clinical and laboratory measures of disease activity.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2886241

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


  7 in total

Review 1.  Combination therapy in rheumatoid arthritis.

Authors:  S Bingham; P Emery
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Response criteria for slow acting antirheumatic drugs.

Authors: 
Journal:  Ann Rheum Dis       Date:  1990-10       Impact factor: 19.103

3.  Intra-articular steroids: confounder of clinical trials.

Authors:  H G Taylor; P D Fowler; M J David; P T Dawes
Journal:  Clin Rheumatol       Date:  1991-03       Impact factor: 2.980

Review 4.  Rational use of disease-modifying antirheumatic drugs.

Authors:  D E Furst
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 5.  Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.

Authors:  C P Rains; S Noble; D Faulds
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

6.  Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus.

Authors:  A A Borg; M J Davis; P T Dawes; M F Shadforth
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

7.  Additive two DMARD therapy of the patients with rheumatoid arthritis.

Authors:  M Yasuda; S Nonaka; T Wada; M Yamamoto; S Shiokawa; Y Suenaga; M Nobunaga
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.